PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.23
+0.13 (+0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.10
Open25.95
Bid16.00 x 100
Ask34.87 x 400
Day's Range25.60 - 26.46
52 Week Range10.65 - 33.22
Volume464,895
Avg. Volume946,073
Market Cap1.217B
Beta2.92
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

    SOUTH PLAINFIELD, N.J. , April 12, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its ...

  • PR Newswire12 days ago

    PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs

    SOUTH PLAINFIELD, N.J. , April 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York ...

  • PR Newswire17 days ago

    PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease

    SOUTH PLAINFIELD, N.J., April 4, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC's Huntington's disease program. The program is optimizing small-molecule compounds—identified using PTC's splicing technology platform—that decrease the production of huntingtin protein. The current compounds have been shown to be orally bioavailable in animals, blood-brain barrier penetrant, and effective in decreasing the amount of huntingtin protein in a mouse model that has the expanded human huntingtin transgene.

  • PR Newswire23 days ago

    PTC Therapeutics Announces Pricing of Public Offering of Common Stock

    In addition, PTC has granted the underwriters an option for a period of 30 days to purchase up to an additional 600,000 shares of common stock at the public offering price, less the underwriting discount. Credit Suisse and Citigroup are acting as lead book-running managers for the offering. RBC Capital Markets is also acting as a book-running manager.

  • PR Newswire24 days ago

    PTC Therapeutics Announces Proposed Public Offering of Common Stock

    SOUTH PLAINFIELD, N.J., March 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. PTC intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 600,000 shares of common stock. Credit Suisse and Citigroup are acting as lead book-running managers for the offering.

  • 3 Reasons Momentum Stock Investors Will Love PTC Therapeutics (PTCT)
    Zackslast month

    3 Reasons Momentum Stock Investors Will Love PTC Therapeutics (PTCT)

    PTC Therapeutics (PTCT) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.

  • PR Newswirelast month

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., March 19, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on March 13, 2018 it approved non-statutory stock options to purchase an aggregate of 25,200 shares of its common stock to six new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on March 13, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • PR Newswirelast month

    FIREFISH Transitions into Pivotal Phase

    SOUTH PLAINFIELD, N.J., March 15, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the FIREFISH study of RG7916 in Type 1 spinal muscular atrophy (SMA) patients has transitioned into its pivotal phase with the dosing the first patient. Spinal muscular atrophy is a rare neuromuscular disorder that is caused by reduced levels of the SMN protein which leads to the loss of motor neurons and results in progressive muscle weakness. RG7916 is an investigational splicing modifier targeting the survival motor neuron 2 (SMN2) RNA, restoring a functional transcript.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PTCT earnings conference call or presentation 6-Mar-18 9:30pm GMT

    Q4 2017 PTC Therapeutics Inc Earnings Call

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence

    NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Associated Presslast month

    PTC Therapeutics posts 4Q profit

    On a per-share basis, the South Plainfield, New Jersey-based company said it had profit of 3 cents. The biopharmaceutical company posted revenue of $78 million in the period. For the year, the company ...

  • PR Newswirelast month

    PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

    - 2017 total revenues of $194M , a 135% increase vs. 2016 - - Full year 2018 net product revenue guidance of $260M to $295M - - Conference call at 4:30 p.m. ET - SOUTH PLAINFIELD, N.J. , March 6, 2018 ...

  • ACCESSWIRE2 months ago

    PTC Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / PTC Therapeutics, Inc. (NASDAQ: PTCT ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018 at 4:30 PM Eastern Time. ...

  • Benzinga2 months ago

    PTC Therapeutics Q4 Earnings Preview

    PTC Therapeutics (NASDAQ: PTCT ) announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue PTC Therapeutics' ...

  • Barrons.com2 months ago

    [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna

    RTW Investments of New York is focused on the health-care sector and its portfolio, valued at $1.1 billion, according to S&P Capital IQ, is populated with many smaller drug developers. In the fourth quarter, the hedge fund made some interesting investment changes in names that had big moves in 2017, including two that tripled in value. RTW exited bluebird bio (BLUE) entirely and initiated a position in Vericel (VCEL).

  • PR Newswire2 months ago

    PTC Therapeutics To Participate At Upcoming Investor Conferences

    SOUTH PLAINFIELD, N.J. , March 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company ...

  • PR Newswire2 months ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Feb. 28, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on February 26, 2018 it approved non-statutory stock options to purchase an aggregate of 96,750 shares of its common stock to sixteen new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on February 26, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • PR Newswire2 months ago

    PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results

    SOUTH PLAINFIELD, N.J. , Feb. 21, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end ...

  • PR Newswire2 months ago

    PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs

    SOUTH PLAINFIELD, N.J., Feb. 20, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for ataluren. In its letter, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway.

  • PR Newswire2 months ago

    PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

    SOUTH PLAINFIELD, N.J., Feb. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) is delighted to announce the launch of the fourth annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne Muscular Dystrophy (DMD). The STRIVE Awards provide funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates.

  • PR Newswire2 months ago

    PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

    SOUTH PLAINFIELD, N.J. , Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global ...

  • PR Newswire3 months ago

    Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Jan. 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Type 1 SMA. Previously published natural history data indicate that in a comparable historic cohort the median age of event-free survival for SMA Type 1 infants to be between 8 and 10.5 months1,2.

  • PR Newswire3 months ago

    Data from RG7916 Programs in SMA to be Presented at the International Scientific Congress on Spinal Muscular Atrophy

    SOUTH PLAINFIELD, N.J., Jan. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that updates and preliminary data from ongoing clinical trials of RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier in SMA patients will be presented at the International Scientific Congress on Spinal Muscular Atrophy at Jagiellonian University, Kraków, Poland from January 25-27th. The first interim analysis of survival and real-life experiences from the FIREFISH clinical trial in infants with Type 1 SMA will be presented, as well as poster presentations on SMN protein production and the safety and pharmacodynamic effects from the clinical trials in Type 2/3 SMA patients.

  • PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%
    Zacks3 months ago

    PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%

    The shares of PTC Therapeutics (PTCT) rose nearly 13% yesterday.